In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first two years of treatment with Janus kinase inhibitors (JAKi) compared to ...

DelveInsight’s "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted ...

Tumor necrosis factor (TNF) inhibitors are a group of biologics that treat both IBD and AS. These medicines block a protein that causes inflammation in the joints in ankylosing spondylitis ...

Acrivon Therapeutics presents data on ACR-2316's tumor cell death mechanisms and early clinical ... its selective WEE1/PKMYT1 inhibitor, at the American Association for Cancer Research Annual ...

This review is the first to summarize the mechanisms of action and resistance associated with both ferroptosis and PARP inhibitors in ovarian cancer. Having established the core mechanisms of ...

Tumor necrosis factor (TNF)-α inhibitors are associated with an increased risk of fungal infections, according to the findings of a systematic review published in Mycoses. Investigators explored ...

The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2F-high cancers.

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2F-high cancers.